Skip to content

Study · Animal study (in vivo) · mouse · 2013

6 results

Omental grafting: a cell-based therapy for blood vessel repair.

Shelton EL, Poole SD, Reese J, Bader DM

Journal of tissue engineering and regenerative medicine8 Feb 2012Cited by 15 (Europe PMC)

PMID22318999 (opens in a new tab)PMCIDPMC3672266 (opens in a new tab)DOI10.1002/term.528 (opens in a new tab)PepBankPUB-22318999
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with carotid artery injury, Tβ4-treated omental grafts induced progenitor cells to fully integrate into the wall of injured vessels.

    In plain wordsIn mice with injured arteries, grafts treated with thymosin beta‑4 sent progenitor cells that merged into the damaged vessel wall.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseIntegration of graft progenitor cells into injured vessel wall
    Study

    mousen: not reported in source

    murine carotid artery injury with labelled omental grafts
    Outcome group
    Wound healing · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We found treatment of grafts with Tβ4-induced progenitor cells to fully integrate into the wall of injured vessels and differentiate into vascular smooth muscle.
    2 context sentences
    Summary · context
    Labelled omental grafts were transplanted into a murine carotid artery injury model.
    Summary · context
    Selected grafts were treated with thymosin β4 (Tβ4) prior to transplantation to investigate the effects of chemical potentiation on healing.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with carotid artery injury, Tβ4-treated omental grafts induced progenitor cells to differentiate into vascular smooth muscle.

    In plain wordsIn mice with injured arteries, grafts treated with thymosin beta‑4 sent cells that became blood vessel muscle.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseDifferentiation of graft progenitor cells into vascular smooth muscle
    Study

    mousen: not reported in source

    murine carotid artery injury with labelled omental grafts
    Outcome group
    Wound healing · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We found treatment of grafts with Tβ4-induced progenitor cells to fully integrate into the wall of injured vessels and differentiate into vascular smooth muscle.
    2 context sentences
    Summary · context
    Labelled omental grafts were transplanted into a murine carotid artery injury model.
    Summary · context
    Selected grafts were treated with thymosin β4 (Tβ4) prior to transplantation to investigate the effects of chemical potentiation on healing.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with carotid artery injury, arteries receiving Tβ4-stimulated grafts were functionally indistinguishable from uninjured controls in myographic studies.

    In plain wordsIn mice, injured arteries that got thymosin beta‑4-treated grafts worked like uninjured arteries.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeArterial function after Tβ4-stimulated grafts
    Study

    mousen: not reported in source

    murine carotid artery injury with labelled omental grafts
    Comparator
    Uninjured controls
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Myographic studies determined that arteries receiving Tβ4-stimulated grafts were functionally indistinguishable from uninjured controls.
    1 context sentence
    Summary · context
    Labelled omental grafts were transplanted into a murine carotid artery injury model.
  4. 04LabIn vitro (cells)Efficacy outcome

    In vitro, Tβ4 promoted proliferation of cells via AKT signalling.

    In plain wordsIn lab tests, thymosin beta‑4 promoted cell growth through AKT signalling.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseCell proliferation
    Study

    n: not reported in source

    in vitro cell analyses
    Outcome group
    Wound healing · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Concurrent in vitro analyses showed that Tβ4 promoted proliferation, migration and trans-differentiation of cells via AKT signalling.
  5. 05LabIn vitro (cells)Efficacy outcome

    In vitro, Tβ4 promoted migration of cells via AKT signalling.

    In plain wordsIn lab tests, thymosin beta‑4 promoted cell migration through AKT signalling.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseCell migration
    Study

    n: not reported in source

    in vitro cell analyses
    Outcome group
    Wound healing · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Concurrent in vitro analyses showed that Tβ4 promoted proliferation, migration and trans-differentiation of cells via AKT signalling.
  6. 06LabIn vitro (cells)Efficacy outcome

    In vitro, Tβ4 promoted trans-differentiation of cells via AKT signalling.

    In plain wordsIn lab tests, thymosin beta‑4 promoted cell type change through AKT signalling.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseCell trans-differentiation
    Study

    n: not reported in source

    in vitro cell analyses
    Outcome group
    Wound healing · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Concurrent in vitro analyses showed that Tβ4 promoted proliferation, migration and trans-differentiation of cells via AKT signalling.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.